Alkermes Shareholders Approve Amendments at Annual Meeting

Alkermes ( (ALKS) ) has issued an update.

On May 21, 2025, Alkermes plc held its annual general meeting where shareholders approved amendments to the 2018 Stock Option and Incentive Plan, increasing the number of authorized shares by 4,250,000. Additionally, shareholders elected directors, approved executive compensation, ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor, and renewed the Board’s authority to allot and issue shares under Irish law, reflecting strong shareholder support for the company’s strategic initiatives.

The most recent analyst rating on (ALKS) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Alkermes stock, see the ALKS Stock Forecast page.

Spark’s Take on ALKS Stock

According to Spark, TipRanks’ AI Analyst, ALKS is a Outperform.

Alkermes demonstrates strong financial performance with excellent profitability and efficient cash generation. The technical indicators suggest limited upward momentum, warranting caution. The stock is fairly valued within its sector. The earnings call highlights solid product growth and R&D progress, but also notes macroeconomic concerns and market dependencies. Overall, Alkermes is well-positioned but faces external challenges that could impact future performance.

To see Spark’s full report on ALKS stock, click here.

More about Alkermes

Alkermes plc operates in the biopharmaceutical industry, focusing on developing innovative medicines for the treatment of central nervous system (CNS) diseases and cancer. The company is known for its proprietary technologies and a diverse portfolio of products targeting major unmet medical needs.

Average Trading Volume: 1,752,784

Technical Sentiment Signal: Buy

Current Market Cap: $5.19B

Find detailed analytics on ALKS stock on TipRanks’ Stock Analysis page.